Inhibitors of poly(adp-ribose) polymerase
AssigneesRhizen Pharmaceuticals SA, Incozen Therapeutics Pvt. Ltd.
InventorsSwaroop Kumar Venkata Satya VAKKALANKA, Debnath BHUNIYA, Srikant VISWANADHA
Life of this patent
Estimating the term…
Abstract
The present invention relates to Poly(ADP-ribose) polymerase (PARP) inhibitors, methods of preparing them, pharmaceutical compositions containing them and to their use in methods of treatment and/or prevention of PARP mediated diseases or disorders.
Claims24
A compound selected from
- (R)-(+)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one hydrochloride;
- (R)-(+)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one benzenesulfonate;
- (R)-(+)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one 4-methyl benzenesulfonate;
- and
- (R)-(+)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one methanesulfonate.
2-5. (canceled)
A compound selected from
- (S)-(−)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one hydrochloride;
- (S)-(−)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one benzenesulfonate;
- (S)-(−)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one 4-methyl benzenesulfonate;
- and
- (S)-(−)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one methanesulfonate.
7-11. (canceled)
A crystalline hydrochloride salt of (R)-(+)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one, wherein the crystalline hydrochloride salt exhibits one or more of:
- a) an X-ray powder diffraction pattern having one or more characteristic peaks at 5.32, 10.65, 14.91, 15.22, 16.68, 19.90, 21.75, 21.99, 23.84, 25.08, and 27.14±0.2° 2θ;
- b) an X-ray powder diffraction pattern substantially as depicted in FIG. 5;
- c) a differential scanning calorimeter pattern with a characteristic endothermic peak of about 228° C.;
- or
- d) a differential scanning calorimeter pattern substantially as depicted in FIG. 1.
13-17. (canceled)
A crystalline benzenesulfonate salt of (R)-(+)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one, wherein the crystalline benzenesulfonate salt exhibits one or more of:
- (a) an X-ray powder diffraction pattern having one or more characteristic peaks at 4.91, 5.42, 13.76, 14.61, 18.47, 21.14, 22.19, 23.07, 23.84, and 25.28±0.2° 2θ;
- (b) an X-ray powder diffraction pattern substantially as depicted in FIG. 6;
- (c) a differential scanning calorimeter pattern with a characteristic endothermic peak of about 231° C.;
- or
- (d) a differential scanning calorimeter pattern substantially as depicted in FIG. 2.
19-23. (canceled)
A crystalline mono-methylbenzene sulfonate salt of (R)-(+)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one, wherein the crystalline mono-methylbenzene sulfonate salt exhibits one or more of:
- (a) an X-ray powder diffraction pattern having one or more peaks at 6.81, 13.22, 13.96, 20.52 21.87, 22.67, and 24.48±0.2° 2θ;
- (b) an X-ray powder diffraction pattern substantially as depicted in FIG. 7A;
- (c) an X-ray powder diffraction (XRPD) pattern having one or more characteristic peaks at 6.98, 13.82, 15.98, 18.50, and 19.50±0.2° 2θ;
- (d) an XRPD pattern substantially as depicted in FIG. 7B;
- (e) a differential scanning calorimeter (DSC) pattern with a characteristic endothermic peak at about 170° C.;
- (f) a differential scanning calorimeter (DSC) pattern substantially as depicted in FIG. 3;
- or
- (g) an XRPD pattern exhibiting one or more peaks selected from 6.98, 13.82, 15.98, 18.50, 19.50±0.05, 0.1, or 0.2° 2θ, and a differential scanning calorimeter (DSC) pattern having a characteristic endothermic peak at about 170° C.
25-31. (canceled)
A crystalline methane sulfonate salt of (R)-(+)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one, wherein the crystalline methane sulfonate salt exhibits one or more of:
- (a) an X-ray powder diffraction pattern having one or more characteristic peaks at 5.84, 11.17, 13.78, 14.60, 19.17, 20.03, 21.32, 22.24, 22.77, 26.40±0.2° 2θ;
- (b) an X-ray powder diffraction pattern substantially as depicted in FIG. 8A;
- (c) an X-ray powder diffraction pattern having one or more characteristic peaks at 5.74, 11.20, 13.69, 14.67, 19.20, 20.05, 21.29, 22.57, 26.38±0.2° 2θ;
- (d) an X-ray powder diffraction pattern substantially as depicted in FIG. 8B;
- (e) an X-ray powder diffraction pattern having one or more characteristic peaks at 5.67, 10.81, 14.34, 19.03, 20.40, 21.96, 23.44, 24.52, and 25.94±0.2° 2θ;
- (f) an X-ray powder diffraction pattern substantially as depicted in FIG. 8C;
- (g) an X-ray powder diffraction pattern having one or more peaks at 5.73, 11.02, 11.19, 13.68, 14.55, 15.11, 19.11, 20.04, 21.28, 22.19, and 22.65, 26.15±0.2° 2θ;
- (h) an X-ray powder diffraction pattern substantially as depicted in FIG. 8D;
- (i) a differential scanning calorimeter pattern with a characteristic endothermic peak in the range between about 165° C. to 175° C.;
- (i) a differential scanning calorimeter pattern with a characteristic endothermic peak in the range between about 190° C. and 220° C.;
- (k) a differential scanning calorimeter pattern with a characteristic endothermic peak of about 205° C.;
- (l) a differential scanning calorimeter pattern substantially as depicted in FIG. 4A;
- (m) exhibits a differential scanning calorimeter pattern with a characteristic endothermic peak of about 208° C.;
- (n) a differential scanning calorimeter pattern substantially as depicted in FIG. 4B;
- (o) a differential scanning calorimeter pattern with a characteristic endothermic peak of about 172° C.;
- (p) a differential scanning calorimeter pattern substantially as depicted in FIG. 4C;
- (q) a differential scanning calorimeter pattern with a characteristic endothermic peak of about 210° C.;
- or
- (r) a differential scanning calorimeter pattern substantially as depicted in FIG. 4D.
33-54. (canceled)
56-58. (canceled)
61-62. (canceled)
(canceled)
Dependencies are inferred from the claim text.